DK0809510T3 - Lymphotoxin-alfa/beta-komplekser og antilymphotoxin-beta-receptorantistoffer som antitumormidler - Google Patents

Lymphotoxin-alfa/beta-komplekser og antilymphotoxin-beta-receptorantistoffer som antitumormidler

Info

Publication number
DK0809510T3
DK0809510T3 DK96906260T DK96906260T DK0809510T3 DK 0809510 T3 DK0809510 T3 DK 0809510T3 DK 96906260 T DK96906260 T DK 96906260T DK 96906260 T DK96906260 T DK 96906260T DK 0809510 T3 DK0809510 T3 DK 0809510T3
Authority
DK
Denmark
Prior art keywords
beta
activating agent
lhc
carrier
lymphotoxin
Prior art date
Application number
DK96906260T
Other languages
English (en)
Inventor
Christopher D Benjamin
Jeffrey L Browning
Werner Meier
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of DK0809510T3 publication Critical patent/DK0809510T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK96906260T 1995-01-26 1996-01-26 Lymphotoxin-alfa/beta-komplekser og antilymphotoxin-beta-receptorantistoffer som antitumormidler DK0809510T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37896895A 1995-01-26 1995-01-26

Publications (1)

Publication Number Publication Date
DK0809510T3 true DK0809510T3 (da) 2004-10-04

Family

ID=23495285

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96906260T DK0809510T3 (da) 1995-01-26 1996-01-26 Lymphotoxin-alfa/beta-komplekser og antilymphotoxin-beta-receptorantistoffer som antitumormidler

Country Status (24)

Country Link
EP (2) EP1407781A1 (da)
JP (2) JPH10513161A (da)
KR (2) KR100470739B1 (da)
CN (3) CN1146442C (da)
AT (1) ATE268604T1 (da)
AU (1) AU725351B2 (da)
BG (1) BG62599B1 (da)
BR (1) BR9606808A (da)
CA (1) CA2211443A1 (da)
CZ (1) CZ298711B6 (da)
DE (1) DE69632681T2 (da)
DK (1) DK0809510T3 (da)
EA (1) EA000096B1 (da)
EE (1) EE04453B1 (da)
ES (1) ES2220972T3 (da)
FI (1) FI119359B (da)
HU (1) HUP9801746A3 (da)
NO (1) NO322744B1 (da)
NZ (1) NZ303405A (da)
PL (1) PL185364B1 (da)
PT (1) PT809510E (da)
RO (1) RO118634B1 (da)
SK (1) SK286497B6 (da)
WO (1) WO1996022788A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7118742B2 (en) * 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
WO2000021558A1 (en) 1998-10-09 2000-04-20 Biogen, Inc. Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
EE200300179A (et) 2000-10-13 2003-08-15 Biogen, Inc. Humaniseeritud LT-ß-R-i vastased antikehad
CA2491480A1 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies
WO2004058191A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
CN1753692A (zh) * 2002-12-20 2006-03-29 比奥根艾迪克Ma公司 淋巴毒素β受体药剂与化疗剂的联合用药
US20050163782A1 (en) 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
SG151294A1 (en) 2004-03-23 2009-04-30 Biogen Idec Inc Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP1764371A1 (de) * 2005-04-25 2007-03-21 Xantos Biomedicine AG Agonistische Antikörper, welche an den LT-Beta-Rezeptor binden und dadurch Adipositas assoziierte Phänotypen modulieren, und deren Verwendung in der Therapie
CN101073665B (zh) * 2006-05-17 2014-11-26 上海复旦张江生物医药股份有限公司 淋巴毒素在制备增加化疗药物敏感性的药物中的应用
EP2067041A2 (en) 2006-10-03 2009-06-10 Biogen Idec MA, Inc. Biomarkers and assays for the treatment of cancer
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
JP2010506955A (ja) 2006-10-20 2010-03-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド 可溶性リンホトキシンβレセプターによる脱髄障害の処置
JP2012504245A (ja) * 2008-09-30 2012-02-16 ジェネンテック， インコーポレイテッド リンホトキシンアンタゴニストに対する関節リウマチの応答性を予測する生物学的マーカー
MX2014006739A (es) * 2011-12-05 2015-06-05 Igenica Biotherapeutics Inc Conjugados de anticuerpo-farmaco y compuestos relacionados, composiciones , y metodos.
EP3750918A1 (en) 2015-01-20 2020-12-16 IGM Biosciences, Inc. Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6124599A (ja) * 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd 新規ヒトインタ−フエロン−ｒポリペプチド誘導体
JPS61277628A (ja) * 1985-06-04 1986-12-08 Asahi Chem Ind Co Ltd 癌治療用白血球刺激材
US4770995A (en) * 1985-08-29 1988-09-13 New York Blood Center, Inc Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin
ATE201879T1 (de) * 1990-06-27 2001-06-15 Biogen Inc Oberflächenkomplexbildung von lymphotoxin
EP0672143B1 (en) * 1992-12-04 2008-06-04 Biogen Idec MA Inc. Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof

Also Published As

Publication number Publication date
CN1146442C (zh) 2004-04-21
CN1900116A (zh) 2007-01-24
RO118634B1 (ro) 2003-08-29
CA2211443A1 (en) 1996-08-01
JPH10513161A (ja) 1998-12-15
PL321758A1 (en) 1997-12-22
DE69632681D1 (de) 2004-07-15
MX9705629A (es) 1997-10-31
HUP9801746A3 (en) 2000-11-28
DE69632681T2 (de) 2005-06-09
FI973118A7 (fi) 1997-09-25
SK98697A3 (en) 2000-02-14
HUP9801746A2 (hu) 1998-11-30
KR19980701816A (ko) 1998-06-25
NO973385L (no) 1997-09-25
KR20040102364A (ko) 2004-12-04
JP2007169296A (ja) 2007-07-05
NZ303405A (en) 2000-02-28
FI119359B (fi) 2008-10-31
PT809510E (pt) 2004-09-30
SK286497B6 (sk) 2008-11-06
CZ298711B6 (cs) 2008-01-02
EE04453B1 (et) 2005-04-15
HK1006356A1 (en) 1999-02-26
KR100470739B1 (ko) 2005-09-02
BG101855A (en) 1998-04-30
BR9606808A (pt) 1997-12-30
WO1996022788A1 (en) 1996-08-01
EP0809510B1 (en) 2004-06-09
FI973118A0 (fi) 1997-07-25
AU725351B2 (en) 2000-10-12
EP0809510A1 (en) 1997-12-03
EA000096B1 (ru) 1998-08-27
NO973385D0 (no) 1997-07-22
CN1177302A (zh) 1998-03-25
EE9700255A (et) 1998-04-15
ES2220972T3 (es) 2004-12-16
NO322744B1 (no) 2006-12-04
PL185364B1 (pl) 2003-04-30
EP1407781A1 (en) 2004-04-14
EA199700144A1 (ru) 1997-12-30
KR100475492B1 (ko) 2005-03-14
AU4970496A (en) 1996-08-14
CN1589902A (zh) 2005-03-09
BG62599B1 (bg) 2000-03-31
ATE268604T1 (de) 2004-06-15
CZ236197A3 (cs) 1998-02-18

Similar Documents

Publication Publication Date Title
DK0809510T3 (da) Lymphotoxin-alfa/beta-komplekser og antilymphotoxin-beta-receptorantistoffer som antitumormidler
Smith et al. Effect of a cancer cachectic factor on protein synthesis/degradation in murine C2C12 myoblasts: modulation by eicosapentaenoic acid
MX9709324A (es) Compuestos terapeuticos que comprenden anticuerpos anti receptores fc.
AU9779498A (en) Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
YU83600A (sh) Adenozin a3 receptorski modulatori
DE69433564D1 (de) Verbindungen die kolorektale krebszellen spezifisch binden und verfahren für ihre herstellung
NO20003552L (no) Progesteron-agonistforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsen, samt en fremgangsmÕte for bestemmelse av tilstedeværelse av steroidreseptorer, ligand-steroidreseptorkomplekser og en fremgangsmÕte
WO1995034320A3 (en) Methods for inhibiting antigen specific t cell responses
KIRKPATRICK et al. Stereospecific glucocorticoid binding to subcellular fractions of the sensitive and resistant lymphosarcoma P1798
DE60029812D1 (de) Diagnose von zellenproliferation sowie screeningverfahren für deren modulatore
DE60018761D1 (de) Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
AU3376297A (en) Human thyrotropin receptor compositions and use thereof
NO970740L (no) Glutamat reseptor
Wang et al. Pharmacokinetic characterization of BMS‐936561, an anti‐CD70 antibody‐drug conjugate, in preclinical animal species and prediction of its pharmacokinetics in humans
AU6270298A (en) Zonula occludens toxin receptors
DK0639275T3 (da) Hidtil ukendte GABAa-receptorundertyper og fremgangsmåder til screening af lægemiddelforbindelser under anvendelse af imidazoquinoxaliner og pyrrolopyimidiner til binding til GABAa-receptorundertyper
PL327066A1 (en) Method of diagnosing and treating squamous cell carcinomas
WO1997041225A3 (en) Mammalian mixed lymphocyte receptors, chemokine receptors [mmlr-ccr]
DK1144666T3 (da) Replikationsdeficient baculovirusekspressionssystem
WO1995016709A3 (en) Anti-mullerian hormone receptor polypeptides and antibodies thereto
TR200103288T2 (tr) Tio-oksindol türevleri
DK0943014T3 (da) Fremgangsmåder til diagnosticering af glaukom og opdagelse af antiglaukome lægemidler
Ramos et al. Next‐generation sequencing of baseline genetic mutations and outcomes of eltrombopag and azacitidine therapy in patients with myelodysplastic syndromes and thrombocytopenia: Data from the SUPPORT clinical trial
NO965347L (no) Fremgangsmåte for fremstilling av cytolytiske T-celler som er spesifikke for et peptid/MHC-kompleks
TR200000957T2 (tr) Hiperglisemi tedavisinde tiazolidinedion kullanımı